July 12, 2017 GAITHERSBURG, Maryland, July 12,
Post# of 104
(Total Views: 673)
Posted On: 07/12/2017 2:28:56 PM
July 12, 2017
GAITHERSBURG, Maryland, July 12, 2017 /PRNewswire/ --
Genetic Health Solution platform helps chronic disease patient management
Patient-centric biomarker-based wellness programs designed to improve outcomes
Avant Diagnostics, Inc. ("Avant"
(OTC: AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, acquired an exclusive option to license the patient-delivery technology platform from Genetic Health Solution ("GHS", website: http://www.genetichealthsolution.com). GHS is a functional medicine practice that specializes in the aggregation and analysis of advanced biomarker testing data to provide tailored product recommendations for health optimization.
As part of the agreement, the management teams of both companies will endeavor to build an oncology-focused personalized health optimization program to improve health outcomes for patients based upon oncology drugs' side effect profiles combined with advanced blood biomarker monitoring. Taken together, the companies believe they can establish a best-in-class personalized cancer patient management program tailored to allow physicians and patients to proactively mitigate potential negative drug side effects, as well as boost overall health.
Concurrent with this announcement, the Company is evaluating an initial Theralink® product launch in breast cancer that will focus on a specific treatment paradigm where our proprietary assay can immediately impact a large population of patients who may be prescribed ineffective treatments due to the insufficient biomarker testing methods currently available. The patient population of interest, with the additional Theralink information, would receive a different prescription therapy that is likely to lead to a well-defined improvement in outcomes based upon the published literature.
About Avant Diagnostics, Inc.
Avant is a healthcare information solutions company that specializes in biomarker tests that are being developed in the areas of oncology and neurology. Avant provides personalized medicine diagnostic testing capabilities through its TheraLink® diagnostic assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders for over 30 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across several different cancer types, including breast, ovarian, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Avant has used these proteomic technologies to support the drug development programs of many of the top biopharmaceutical companies in the world. More information can be found at the website for the Company's wholly-owned subsidiary Theranostics Health at http://www.theranosticshealth.com.
Avant is also developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated proteomic microarray-based test that measures the activation of the immune system markers in blood samples in response to ovarian tumor cell development.
Avant's neurology division was recently acquired from Amarantus Bioscience Holdings, Inc. (OTC: AMBS) and owns certain rights to next-generation DNA sequencing (NGS) assay for the identification of patients with autoimmune disorders, and has an exclusive license to The LymPro Test™ for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig. The Company also owns intellectual property for the proteomic-based diagnosis of Parkinson's disease (NuroPro), and other cell-cycle-related disorders.
http://www.avantdiagnostics.com/news-media/pr...to-license
GAITHERSBURG, Maryland, July 12, 2017 /PRNewswire/ --
Genetic Health Solution platform helps chronic disease patient management
Patient-centric biomarker-based wellness programs designed to improve outcomes
Avant Diagnostics, Inc. ("Avant"
(OTC: AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, acquired an exclusive option to license the patient-delivery technology platform from Genetic Health Solution ("GHS", website: http://www.genetichealthsolution.com). GHS is a functional medicine practice that specializes in the aggregation and analysis of advanced biomarker testing data to provide tailored product recommendations for health optimization. As part of the agreement, the management teams of both companies will endeavor to build an oncology-focused personalized health optimization program to improve health outcomes for patients based upon oncology drugs' side effect profiles combined with advanced blood biomarker monitoring. Taken together, the companies believe they can establish a best-in-class personalized cancer patient management program tailored to allow physicians and patients to proactively mitigate potential negative drug side effects, as well as boost overall health.
Concurrent with this announcement, the Company is evaluating an initial Theralink® product launch in breast cancer that will focus on a specific treatment paradigm where our proprietary assay can immediately impact a large population of patients who may be prescribed ineffective treatments due to the insufficient biomarker testing methods currently available. The patient population of interest, with the additional Theralink information, would receive a different prescription therapy that is likely to lead to a well-defined improvement in outcomes based upon the published literature.
About Avant Diagnostics, Inc.
Avant is a healthcare information solutions company that specializes in biomarker tests that are being developed in the areas of oncology and neurology. Avant provides personalized medicine diagnostic testing capabilities through its TheraLink® diagnostic assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders for over 30 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across several different cancer types, including breast, ovarian, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Avant has used these proteomic technologies to support the drug development programs of many of the top biopharmaceutical companies in the world. More information can be found at the website for the Company's wholly-owned subsidiary Theranostics Health at http://www.theranosticshealth.com.
Avant is also developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated proteomic microarray-based test that measures the activation of the immune system markers in blood samples in response to ovarian tumor cell development.
Avant's neurology division was recently acquired from Amarantus Bioscience Holdings, Inc. (OTC: AMBS) and owns certain rights to next-generation DNA sequencing (NGS) assay for the identification of patients with autoimmune disorders, and has an exclusive license to The LymPro Test™ for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig. The Company also owns intellectual property for the proteomic-based diagnosis of Parkinson's disease (NuroPro), and other cell-cycle-related disorders.
http://www.avantdiagnostics.com/news-media/pr...to-license
(1)
(0)